logo
Plus   Neg
Share
Email

Britvic Fiscal Year Pretax Profit Rises - Quick Facts

Britvic plc (BVIC.L) reported pretax profit of 137.6 million pounds for the 52 weeks ended 27 September 2015 compared to 120.1 million pounds, a year ago. Profit for the period attributable to the equity shareholders increased to 103.8 million pounds or 41.2 pence per share from 89.7 million pounds or 36.2 pence per share. Adjusted earnings per share increased to 45.7 pence from 41.5 pence.

Revenue decreased to 1.30 billion pounds from 1.34 billion pounds, previous year. The Group reported slight revenue decline of 0.6%, with volume growth of 0.9% and ARP decline of 1.5%.

The board of Britvic recommended a final dividend of 16.3 pence per share, an increase of 10.1% on the dividend declared last year. The final dividend will be paid on 5 February 2016 to shareholders on record as at 4 December 2015.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT